Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response

被引:6
|
作者
Gu, Tianwei [1 ]
Hong, Ting [1 ]
Zhang, Pengzi [1 ]
Tang, Sunyinyan [1 ]
Bi, Yan [1 ]
Lu, Hai [2 ]
Men, Lichuang [2 ]
Ma, Dongwei [2 ]
Zhu, Dalong [1 ]
机构
[1] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[2] Sanofi Investment Co Ltd, Shanghai, Peoples R China
关键词
Asia; Basal insulin; China; Dose titration; Insulin glargine 100 U/mL; Nomogram; Pooled analysis; Type 2 diabetes mellitus; BODY-MASS INDEX; BASAL INSULIN; OBSERVATIONAL REGISTRY; PREMIXED INSULIN; TREATMENT ORBIT; UNITED-STATES; NPH INSULIN; TITRATION; THERAPY; TARGET;
D O I
10.1007/s13300-018-0381-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: In Asia, patients with type 2 diabetes mellitus (T2DM) often have suboptimal glycemic control for many years prior to initiating basal insulin. Active titration of basal insulin is also required to improve glycemic outcomes. This pooled analysis was conducted to determine the impact of patient baseline covariates on the required dose of basal insulin and treatment response, for the improved management of Asian patients with T2DM. Methods: Data on insulin-naive Asian patients with T2DM who initiated and fully titrated insulin glargine 100 U/mL (Gla-100) for >= 20 weeks were pooled from seven randomized, controlled, treat-to-target trials. Covariance and multivariate linear/logistic regression analyses were applied to determine the impact of the baseline covariates on Gla-100 dose (primary outcome) and treatment response (secondary outcomes) at week 24 for patients from Asia (N = 724) and from China alone (n = 249). Based on the multivariate analysis for the primary outcome in the Asian population, a nomogram was developed. Results: The dose of Gla-100 at week 24 was negatively correlated with age and positively correlated with body mass index (BMI) and fasting plasma glucose (FPG) at baseline in both Asian and Chinese populations. In both populations, higher baseline glycated hemoglobin (HbA(1c)) was associated with a lower reduction in HbA1c from baseline, higher HbA(1c) at week 24, and a lower chance of achieving HbA(1c) < 7% at week 24. The constructed nomogram enables calculation of the likely dose of Gla-100 required by Asian patients with T2DM to achieve HbA(1c) < 7% at week 24. Conclusions: Higher doses of Gla-100 are likely to be required in younger patients or patients with higher baseline BMI or FPG. The nomogram developed in this study can aid clinicians to titrate the dose of Gla-100 appropriately. Evidence in this pooled analysis also indicates that initiating basal insulin at a lower HbA(1c) can lead to greater glycemic control.
引用
收藏
页码:771 / 787
页数:17
相关论文
共 50 条
  • [1] Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response
    Tianwei Gu
    Ting Hong
    Pengzi Zhang
    Sunyinyan Tang
    Yan Bi
    Hai Lu
    Lichuang Men
    Dongwei Ma
    Dalong Zhu
    Diabetes Therapy, 2018, 9 : 771 - 787
  • [2] Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus
    Liu, Sung-Chen
    Chuang, Shih-Ming
    Wang, Chao-Hung
    Chien, Ming-Nan
    Lee, Chun-Chuan
    Chen, Wei-Che
    Leung, Ching-Hsiang
    Lin, Jiun-Lu
    DIABETES OBESITY & METABOLISM, 2023, 25 (03) : 700 - 706
  • [3] A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus - a systematic review and meta-analysis
    Rys, P.
    Wojciechowski, P.
    Siejka, S.
    Malecki, P.
    Hak, L.
    Malecki, M. T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (03) : 304 - 313
  • [4] Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
    Wang, Zhihui
    Hedrington, Maka S.
    Joy, Nino Gogitidze
    Briscoe, Vanessa J.
    Richardson, M. Antoinette
    Younk, Lisa
    Nicholson, Wendell
    Tate, Donna B.
    Davis, Stephen N.
    DIABETES CARE, 2010, 33 (07) : 1555 - 1560
  • [5] Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
    Takahisa Hirose
    Ching-Chu Chen
    Kyu Jeung Ahn
    Jacek Kiljański
    Diabetes Therapy, 2019, 10 : 805 - 833
  • [6] Comparison of Safety and Efficacy of Insulin Glargine and Neutral Protamine Hagedorn Insulin in Older Adults with Type 2 Diabetes Mellitus: Results from a Pooled Analysis
    Lee, Pearl
    Chang, Annette
    Blaum, Caroline
    Vlajnic, Aleksandra
    Gao, Ling
    Halter, Jeffrey
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 (01) : 51 - 59
  • [7] Insulin glargine compared with premixed insulin for management of insulin-naive type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study
    Aschner, Pablo
    Sethi, Bipin
    Gomez-Peralta, Fernando
    Landgraf, Wolfgang
    Loizeau, Virginie
    Dain, Marie-Paule
    Pilorget, Valerie
    Comlekci, Abdurrahman
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (06) : 838 - 845
  • [8] DIABETES DURATION AND THE EFFICACY AND SAFETY OF INSULIN GLARGINE VERSUS COMPARATOR TREATMENT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Garg, Satish K.
    Aurand, Lisa A.
    Rimler, Michael S.
    Dailey, George E.
    ENDOCRINE PRACTICE, 2014, 20 (02) : 120 - 128
  • [9] Use of Insulin Glargine 100U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
    Hirose, Takahisa
    Chen, Ching-Chu
    Ahn, Kyu Jeung
    Kiljanski, Jacek
    DIABETES THERAPY, 2019, 10 (03) : 805 - 833
  • [10] New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
    Goldman, Jennifer
    White, John R., Jr.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (10) : 1153 - 1161